SiRNA structural optimization
siRNA结构优化
基本信息
- 批准号:7682138
- 负责人:
- 金额:$ 21.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:AffectAntiviral TherapyBindingBioavailableBiological AssayCCR5 geneCellsCellular MorphologyChemicalsClassClinicalComplexCultured CellsDrug FormulationsEpisomeFluorescence PolarizationFocal Adhesion Kinase 1Gene SilencingGenesGenomeGoalsGrowthHIVHead and Neck NeoplasmsHuman Herpesvirus 2Human PapillomavirusHuman papillomavirus 16HydrophobicityInfectionInterferonsKineticsLaboratoriesLocal MicrobicidesMacacaMacaca mulattaMaintenanceMalignant NeoplasmsMeasuresModelingModificationMucous MembraneMusNIH Program AnnouncementsPVRL1PlayPreventionPropertyProteinsPyrimidinePyrimidinesRNA InterferenceRNA-Induced Silencing ComplexResearchResearch PersonnelRibonucleosidesRoleSimplexvirusSmall Interfering RNAStructureTestingTissuesToxic effectTransgenic MiceTransgenic OrganismsVaginaVertebral columnViralViral GenomeVirus DiseasesWorkcell growthcell transformationcytotoxiccytotoxicitydesignenhanced green fluorescent proteinhuman DICER1 proteinkeratinocytelocked nucleic acidmeltingmicrobicidemouse modelmucosal uptakenovelnucleasephosphodiesterpre-clinicalprogramsprotein expressionresponseribosidesiRNA Microbicidessizetransmission processvirus episome maintenance
项目摘要
Human papillomaviruses (HPVs) are a major cause of anogenital and head and neck neoplasms and malignancies.
Unfortunately, no specific antiviral therapies for HPV infection or HPV-induced malignancies have been identified.
This U19 proposal is submitted as project by Alexander in a consortium proposal entitled siRNA Microbicides. The goal of this
research consortium is to develop native and chemically modified siRNAs as effective means for blocking
transmission of HIV, HSV2 and HPV. In project by Alexander, we hypothesize that chemically modified single-stranded
boranophosphate-backbone short interfering RNAs (siRNAs) are superior to native siRNAs for potent and durable
gene silencing, and that anti-HPV E6/E7 single-stranded boranophosphate-backbone siRNAs (ssBP-siRNAs) can be
used to effectively block HPV viral replication and proliferation of HPV-transformed cells. By combining chemical
modifications shown individually to increase siRNA silencing potency and duration, we will create ssBP-siRNAs,
designed for topical delivery, that block episome replication in HPV-infected cells and induce irreversible growth
arrest in HPV16-transformed cells. Anti-HPV16 ssBP-siRNAs identified by us will be tested in project 3 using novel
cell culture and transgenic mouse models of HPV infection.
Project 3 will also supply optimized ssBP-siRNAs to projects by Ramratnam and Herold to allow comparison of ssBP-siRNAs with
conventional siRNAs for targeting expression of macaque CCR5, murine focal adhesion kinase, and murine nectin-1.
To allow immediate work optimizing ssBP-siRNA delivery to vaginal mucosa, we will supply existing highly active
ssBP-siRNAs to Core B (Formulations). The vaginal mucosal uptake and activity of formulated ssBP-siRNAs will be
assessed quantitatively in project 3.
At the conclusion of this study, we will have developed anti-HPV16 E6/E7 ssBP-siRNAs as effective topical
microbicides for prevention of HPV infection and HPV-induced malignancies. We will also have created high potency
ssBP-siRNAs active against other consortium targets, and forwarded these ssBP-siRNAs for microbicidal testing in
laboratory models of viral infection.
人乳头瘤病毒(HPV)是导致肛门、头颈部肿瘤和恶性肿瘤的主要原因。
不幸的是,目前还没有针对HPV感染或HPV引起的恶性肿瘤的特效抗病毒疗法。
这份U19提案是Alexander在题为siRNA杀微生物剂的财团提案中作为项目提交的。这样做的目的是
研究联盟将开发天然的和化学修饰的siRNA作为阻断的有效手段
艾滋病毒、单纯疱疹病毒2型和人乳头瘤病毒的传播。在Alexander的项目中,我们假设化学修饰的单链
以硼磷为骨架的短干扰RNA(SiRNAs)在效力和持久性方面优于天然siRNA
基因沉默,以及抗HPV E6/E7单链硼磷酸盐骨架siRNAs(ssBP-siRNAs)可以
用于有效阻断HPV病毒复制和HPV转化细胞的增殖。通过将化学物质
为了增加siRNA沉默的效力和持续时间,我们将创建ssBP-siRNA,
设计用于局部给药,阻止HPV感染细胞中的Episome复制并诱导不可逆转的生长
在HPV16转化的细胞中发生停滞。我们鉴定的抗HPV16单链BP-siRNAs将在项目3中使用新颖的
人乳头瘤病毒感染的细胞培养和转基因小鼠模型。
项目3还将向Ramratnam和Herold的项目提供优化的ssBP-siRNA,以便将ssBP-siRNA与
用于靶向表达猕猴CCR5、鼠粘着斑激酶和鼠Nectin-1的常规siRNAs。
为了立即优化ssBP-sirna对阴道粘膜的输送,我们将为您提供现有的高活性
SSBP-siRNAs到核心B(配方)。配制的ssBP-siRNAs的阴道粘膜摄取和活性将是
在项目3中进行了定量评估。
在这项研究结束时,我们将开发出抗HPV16E6/E7ssBP-siRNAs作为有效的局部治疗药物
用于预防人乳头瘤病毒感染和人乳头瘤病毒诱发恶性肿瘤的杀微生物剂。我们还将创造出高效的
抗其他联盟靶标的ssBP-siRNAs,并将这些ssBP-siRNAs转发给
病毒感染的实验室模型。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KENNETH A ALEXANDER其他文献
KENNETH A ALEXANDER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KENNETH A ALEXANDER', 18)}}的其他基金
Anti-HPV RNA Interference Using Modified RNA's
使用修饰 RNA 进行抗 HPV RNA 干扰
- 批准号:
6935803 - 财政年份:2004
- 资助金额:
$ 21.35万 - 项目类别:
Anti-HPV RNA Interference Using Modified RNA's
使用修饰 RNA 进行抗 HPV RNA 干扰
- 批准号:
6825551 - 财政年份:2004
- 资助金额:
$ 21.35万 - 项目类别:
Anti-HPV RNA Interference Using Modified RNA's
使用修饰 RNA 进行抗 HPV RNA 干扰
- 批准号:
7316076 - 财政年份:2004
- 资助金额:
$ 21.35万 - 项目类别:
COORDINATED CONTROL OF HPV TRANSCRIPTION AND REPLICATION
HPV 转录和复制的协调控制
- 批准号:
6513536 - 财政年份:2000
- 资助金额:
$ 21.35万 - 项目类别:
COORDINATED CONTROL OF HPV TRANSCRIPTION AND REPLICATION
HPV 转录和复制的协调控制
- 批准号:
6193673 - 财政年份:2000
- 资助金额:
$ 21.35万 - 项目类别:
COORDINATED CONTROL OF HPV TRANSCRIPTION AND REPLICATION
HPV 转录和复制的协调控制
- 批准号:
6377120 - 财政年份:2000
- 资助金额:
$ 21.35万 - 项目类别:
相似海外基金
Dose Flexible Combination 3D-Printed Delivery Systems for Antiviral Therapy in Children
用于儿童抗病毒治疗的剂量灵活组合 3D 打印输送系统
- 批准号:
10682185 - 财政年份:2023
- 资助金额:
$ 21.35万 - 项目类别:
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
- 批准号:
475843 - 财政年份:2022
- 资助金额:
$ 21.35万 - 项目类别:
Studentship Programs
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
- 批准号:
474485 - 财政年份:2022
- 资助金额:
$ 21.35万 - 项目类别:
Studentship Programs
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
- 批准号:
10683329 - 财政年份:2022
- 资助金额:
$ 21.35万 - 项目类别:
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
- 批准号:
10481430 - 财政年份:2022
- 资助金额:
$ 21.35万 - 项目类别:
An interdisciplinary approach towards antiviral therapy discovery
抗病毒疗法发现的跨学科方法
- 批准号:
nhmrc : 1196520 - 财政年份:2021
- 资助金额:
$ 21.35万 - 项目类别:
Investigator Grants
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
- 批准号:
10260234 - 财政年份:2021
- 资助金额:
$ 21.35万 - 项目类别:
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
- 批准号:
10548114 - 财政年份:2021
- 资助金额:
$ 21.35万 - 项目类别:
Disparities in the Diffusion of Direct-Acting Antiviral Therapy for Hepatitis C among Baby Boomers: A Mixed-Methods Study
婴儿潮一代丙型肝炎直接作用抗病毒疗法传播的差异:一项混合方法研究
- 批准号:
10400318 - 财政年份:2020
- 资助金额:
$ 21.35万 - 项目类别:
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial)
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)
- 批准号:
449805 - 财政年份:2020
- 资助金额:
$ 21.35万 - 项目类别:
Studentship Programs